Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG)

H.Iwata; M.Sawaki; Y.Sato; M.Wada; T.Toyama; E.Sasaki; Y.Yatabe; T.Imai

首页> 外文期刊>European Journal of Cancer Supplements >Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG)

【24h】

Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG)

机译：多西紫杉醇和曲妥珠单抗联合术前全身治疗术后局部晚期HER2过表达的乳腺癌患者的生物标志物（P PTEN和IGF-IR）分析（Tokai乳腺癌临床研究组：TBCRG）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第7期|共2页
作者
H.Iwata; M.Sawaki; Y.Sato; M.Wada; T.Toyama; E.Sasaki; Y.Yatabe; T.Imai;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG) [J] . H.Iwata, M.Sawaki, Y.Sato, European Journal of Cancer Supplements . 2008,第7期

机译：多西紫杉醇和曲妥珠单抗联合术前全身治疗术后局部晚期HER2过表达的乳腺癌患者的生物标志物（P PTEN和IGF-IR）分析（Tokai乳腺癌临床研究组：TBCRG）
2. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. [J] . Sawaki M, Iwata H, Sato Y, The Breast : . 2010,第5期

机译：多西他赛联合曲妥珠单抗联合术前局部治疗HER-2过表达的乳腺癌的II期临床研究。
3. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predict Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer [J] . Kogawa Takahiro, Fouad Tamer M., Liu Diane D., The oncologist . 2016,第1期

机译：HER2 / Centromeric高探针探针对17号染色体荧光原位杂交比率预测接受曲妥珠单抗新辅助治疗的HER2过表达局部晚期乳腺癌的患者的病理完全缓解和生存结果
4. Preliminary evaluation of preoperative chemohormonotherapy-induced reduction of the functional infrared imaging score in patients with locally advanced breast cancer [C] . Keyserlingk, J.R., Yassa, Engineering in Medicine and Biology Society, 2001. Proceedings of the 23rd Annual International Conference of the IEEE . 2001

机译：局部晚期乳腺癌患者术前化学激素诱导的功能性红外成像评分降低的初步评估
5. Diffusion-weighted magnetic resonance imaging in monitoring treatment response in patients with locally advanced breast cancer. [D] . Singer, Lisa. 2010

机译：扩散加权磁共振成像可监测局部晚期乳腺癌患者的治疗反应。
6. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer [O] . Takahiro Kogawa, Tamer M. Fouad, Diane D. Liu, 2016

机译：高的HER2 / Centromeric探针对17号染色体荧光原位杂交比率预测接受曲妥珠单抗新辅助治疗的HER2过表达局部晚期乳腺癌的患者的病理完全缓解和生存结果
7. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer [O] . 2018

机译：用Pertuzumab，Trastuzumab和Docetaxel进行高级HER2阳性乳腺癌的组合治疗中的家庭（HER1-4）表达作为生物标志物

Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG)

著录项

相似文献

相关主题

期刊订阅